YL-109

• CAT Number: I003337
• CAS Number: 36341-25-0
• Molecular Formula: C14H11NO2S
• Molecular Weight: 257.31
• Purity: ≥95%
• Target: Aryl Hydrocarbon Receptor
• Solubility: 10 mM in DMSO
• Storage: Store at -20°C
• IC50: 85.7 nM(MCF-7 cells proliferation)
• IUPAC Name: 4-(1,3-benzothiazol-2-yl)-2-methoxyphenol
• InChI: InChI=1S/C14H11NO2S/c1-17-12-8-9(6-7-11(12)16)14-15-10-4-2-3-5-13(10)18-14/h2-8,16H,1H3
• InChIKey: KRVBOHJNAFQFPW-UHFFFAOYSA-N
• SMILES: COC1=C(C=CC(=C1)C2=NC3=CC=CC=C3S2)O

YL-109（Cat No.:I003337）is a small molecule compound that acts as a selective inhibitor of the Bruton’s tyrosine kinase (BTK), a key enzyme in the B-cell receptor (BCR) signaling pathway. BTK plays a crucial role in the activation and proliferation of B cells, which are involved in immune responses and are implicated in various autoimmune diseases and cancers, including B-cell malignancies like lymphoma and leukemia. YL-109 is being investigated for its potential therapeutic applications in treating conditions such as chronic lymphocytic leukemia (CLL) and rheumatoid arthritis by blocking BTK-mediated signaling and modulating immune responses.

Reference

[1]. Hiyoshi H, et al. 2-(4-Hydroxy-3-methoxyphenyl)-benzothiazole suppresses tumor progression and metastatic potential of breast cancer cells by inducing ubiquitin ligase CHIP. Sci Rep. 2014 Nov 18;4:7095.